APYX Stock Forecast & Price Target

Apyx Medical is expected to experience continued growth and profitability as they expand their product offerings and enter new markets, such as China and South Korea. The company's focus on surgical aesthetics and its innovative products like AYON have received positive feedback and are expected to address the growing demand for surgical-quality procedures. While there are risks such as competition and regulation, Apyx Medical's rebranding and improved financials suggest a promising future for the company.

Apyx Medical is currently seeing accelerating revenue growth and expense control as reflected in their recent Q4 adj. EBITDA profitability; however, inconsistent commercial execution, slowdown in procedure volumes, competition, pricing pressure, negative clinical trial updates, regulatory delays, margin pressure, supply chain challenges, geopolitical instability, tariffs, and negative financing developments pose risks to their rating and price target of $6.00 (4.7x EV/sales multiple on FY26E sales estimate of $54.3M, $33M in cash, $34.6M in debt, and 44.1M diluted shares outstanding). Additionally, their Renuvion and J-Plasma products have shown promising clinical results but have faced continued pressure in the market.